QALQONSIMON BEZ TUGUNLARINING DIFFERENTSIAL DIAGNOSTIKASIDA IMMUNOHISTOKIMYOVIY MARKERLAR
##article.subject##:
immunohistokimyo, qalqonsimon bez tugunlari, HBME-1, CK19, Galektin-3##article.abstract##
Xulosa: Immunogistokimyo qalqonsimon bez tugunlarining karsinogenezini diagnostika qilishning qimmatli zamonaviy, ammo hozirda kam o'rganilgan usuli hisoblanadi. Maqolada galektin-3, HBME-1, CK-19, TPO, CD-10 kabi qalqonsimon bez tugunlarining diagnostikasi va differensial diagnostikasida qo'llaniladigan immunohistokimyoviy markerlar muhokama qilinadi. Galektin-3 yuqori sezuvchanlikka (73% dan) va o'ziga xoslikka (81,8% dan) ega. HBME-1 galektin-3 ga nisbatan yuqori sezuvchanlikka ega (94%), lekin sezgirligi past (77,8%). CK19 nafaqat papiller saraton, balki follikulyar adenomalarda ham aniqlanadi va ekspressiya darajasi 75% dan yuqori bo'lsa, sezgirlik 77% ni tashkil qiladi va o'ziga xoslik 100% ga etadi. IGMni bitta panelda birlashtirish sezgirlik va o'ziga xoslikni yaxshilaydi.
Библиографические ссылки
Ismailov S.I., Rashitov M.M. Progress in the field of iodine deficiency disorders prevention in Republic of Uzbekistan (1998–2016). Clinical and experimental thyroidology. 2016;12(3):20-24. (In Russ.) https://doi.org/10.14341/ket2016320-24
Arcolia V, Journe F, Renaud F, et al. (2017). Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer. Oncol Lett, 14(4):4183-4189. doi: 10.3892/ol.2017.6719.
Bartolazzi A, Orlandi F, Saggiorato E, et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 2008;9(6):543-549. doi:10.1016/S1470-2045(08)70132-3
Carpi, A, Naccarato AG, Iervasi G, et al. Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer. 2006;95(2):204-209. doi:10.1038/sj.bjc.6603232
Chen Y.J., Zhao RM, Zhao Q, et al. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma. Tumour Biol. 2016;37(7):8715-8720.
Dencic TM, Savin SB, Selemetjev SA, et al. (2015). Strong expression of HBME-1 associates with high-risk clinicopathological factors of papillary thyroid carcinoma. Pathol Oncol Res.;21(3):735-42. doi: 10.1007/s12253-014-9883-6.
Dwivedi SS, Khandeparkar SG, Joshi AR, et al. (2016). Study of Immunohistochemical Markers (CK-19, CD-56, Ki-67, p53) in Differentiating Benign and Malignant Solitary Thyroid Nodules with special Reference to Papillary Thyroid Carcinomas. J Clin Diagn Res;10(12):EC14-EC19. doi: 10.7860/JCDR/2016/22428.9114.
Gabal SM, Salem MM, Mostafa RR, et al. (2018).Role of CD10 Marker in Differentiating Malignant Thyroid Neoplasms from Benign Thyroid Lesions (Immunohistochemical & Histopathological Study). J Med Sci;19;6(12):2295-2300. doi: 10.3889/oamjms.2018.456.
Guhanandam H, Rajamani R, Noorunnisa N, et al. (2016).Expression of Cytokeratin-19 and Thyroperoxidase in Relation to Morphological Features in Non-Neoplastic and Neoplastic Lesions of Thyroid. J Clin Diagn Res.;10(6):EC01-3. doi: 10.7860/JCDR/2016/18522.7919.
Kogan E.A., Petunina N.A., Chernyshova T.V., Lukyanchenko D.V. Determination of galectin-3 expression in the tissue of follicular thyroid tumors. Clinical and experimental thyroidology. 2011;7(1):45-49. (In Russ.) https://doi.org/10.14341/ket20117145-49
Mu C, Ming X, Tian Y, et al. (2022). Mapping global epidemiology of thyroid nodules among general population: A systematic review and meta-analysis. Front. Oncol. 12:1029926. doi: 10.3389/fonc.2022.1029926
Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol. 2006;19(12):1631-1637. doi:10.1038/modpathol.3800705
Noroozinia F, Gheibi A, Ilkhanizadeh B, et al. (2016).CK19 is a useful marker in distinguishing follicular variant of papillary thyroid carcinoma from benign thyroid lesions with follicular growth pattern. Acta Endocrinol (Buchar);12(4):387-391. doi: 10.4183/aeb.2016.387.
Rigau V, Martel B, Evrard C, et al. (2001). Intérêt de l'HBME-1 en pathologie thyroïdienne [HBME-1 immunostaining in thyroid pathology]. Ann Pathol;21(1):15-20.
SaggioratoE, De Pompa R, Volante M, et al. (2005). Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocrine-Related Cancer Endocr Relat Cancer,12(2);305-317doi.org/10.1677/erc.1.00944
Seifert P, Schenke S, Zimny M, et al. (2021). Diagnostic Performance of Kwak, EU, ACR, and Korean TIRADS as Well as ATA Guidelines for the Ultrasound Risk Stratification of Non-Autonomously Functioning Thyroid Nodules in a Region with Long History of Iodine Deficiency: A German Multicenter Trial. Cancers,13,4467doi.org/ 10.3390/cancers13174467
